Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06957314 · ClinicalTrials.gov registry record · NA
A Study of Hospital-at-Home for People Receiving Tarlatamab
A NA study of Small-cell Lung Cancer and Small Cell Lung Carcinoma, sponsored by Memorial Sloan Kettering Cancer Center.
- Recruiting
- Registry status
- NA
- Development phase
- 70
- Enrollment target
- 7
- Study locations
NCT06957314: Recruiting NA study of Small-cell Lung Cancer and Small Cell Lung Carcinoma, sponsored by Memorial Sloan Kettering Cancer Center.
NCT06957314 is a NA study of Small-cell Lung Cancer and Small Cell Lung Carcinoma that is actively recruiting participants, run by Memorial Sloan Kettering Cancer Center. The registered enrollment target is 70 participants, below the 231-participant average among 79 other Small-cell Lung Cancer trials with a reported enrollment target (70% lower). The trial reports 7 study locations across 2 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT06957314, a NA study of Small-cell Lung Cancer and Small Cell Lung Carcinoma, is actively recruiting participants, sponsored by Memorial Sloan Kettering Cancer Center.
- RECRUITING
- Registry status
- NA
- Development phase
- 70 participants
- Enrollment target
- 7
- Study locations
Study Summary
The purpose of this study is to find out whether a Hospital-at-Home (HaH) program is a more efficient way to monitor people's health after receiving tarlatamab than monitoring in the hospital (inpatient).
Primary Outcome
Evaluate whether HaH in combination with an enhanced oncology specific telemedicine platform is efficient by quantifying inpatient hospital days during the two 7-day periods (14 days total) after the tarlatamab infusions scheduled for C1D1 and C1D8
Conditions Studied
Interventions
- OTHER Hospital-at-Home/HAH
Study Locations (7)
New York
- Memorial Sloan Kettering Suffolk- Commack (Consent Only) - Commack
- Memorial Sloan Kettering Westchester (Consent only) - Harrison
- Memorial Sloan Kettering Cancer Center (All Protocol Activites) - New York
- Memorial Sloan Kettering Nassau (Consent only) - Uniondale
New Jersey
- Memorial Sloan Kettering at Basking Ridge (Consent only) - Basking Ridge
- Memorial Sloan Kettering Monmouth (Consent only) - Middletown
- Memorial Sloan Kettering Bergen (Consent Only) - Montvale
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 70 participants |
| Start Date | 2025-04-23 |
| Est. Completion | 2028-04-23 |
| Phase | NA |
What NCT06957314 shows while recruiting
NCT06957314 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 70 participants, a relatively small participant target, below the 231-participant average among 79 other Small-cell Lung Cancer trials with a reported enrollment target (70% lower).
The record links to 2 conditions, with Small-cell Lung Cancer appearing as the primary indexed condition, and to 1 intervention - of which Hospital-at-Home/HAH is the first listed.
NCT06957314 lists 7 locations in 2 states (New York, New Jersey).
Frequently Asked Questions
What is clinical trial NCT06957314 about?
NCT06957314 is a clinical study titled "A Study of Hospital-at-Home for People Receiving Tarlatamab". The purpose of this study is to find out whether a Hospital-at-Home (HaH) program is a more efficient way to monitor people's health after receiving tarlatamab than monitoring in the hospital (inpatient).
What is the current status of trial NCT06957314?
This trial is currently recruiting. It is a NA study. The enrollment target is 70 participants. The study started on 2025-04-23. Estimated completion is 2028-04-23.
What conditions does trial NCT06957314 study?
This clinical trial studies the following conditions: Small-cell Lung Cancer, Small Cell Lung Carcinoma.
What interventions are being tested in trial NCT06957314?
The interventions under investigation include: Hospital-at-Home/HAH (OTHER).
Who is sponsoring clinical trial NCT06957314?
This trial is sponsored by Memorial Sloan Kettering Cancer Center, which has 1,884 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06957314 being conducted?
This trial has 7 study locations across New Jersey, New York. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Small-cell Lung Cancer
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT06957314's enrollment target sits among peer trials
70 43rd of 79 higher than 36 of 79 other Small-cell Lung Cancer trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Small-cell Lung Cancer trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Prospective Study of Intensity-Modulated Proton Therapy (IMPT) for Small Cell Lung Cancer
RECRUITING · NA
-
LOcally ABLatIve ThErapy for OligopRogressive Lung And Thoracic MalignanciEs (OBLITERATE)
RECRUITING · NA
-
Comparing Single vs Multiple Dose Radiation for Cancer Patients With Brain Metastasis and Receiving Immunotherapy
RECRUITING · NA
-
Stereotactic Radiation in Patients With Small Cell Lung Cancer and 1-10 Brain Metastases
ACTIVE NOT RECRUITING · NA
-
Hippocampal Prophylactic Cranial Irradiation for Small Cell Lung Cancer
COMPLETED · NA
-
A Study of IDE849 in Patients With DLL3 Expressing Tumors Including Small Cell Lung Cancer
RECRUITING · Phase 1
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00969111 · 70 participants · NA
Postoperative or Salvage Radiotherapy (RT) for Node Negative Prostate Cancer Following Radical Prostatectomy
- NCT01712620 · 70 participants · Phase 2
Spironolactone for Pulmonary Arterial Hypertension
- NCT02143830 · 70 participants · Phase 2
HSCT for Patients With Fanconi Anemia Using Risk-Adjusted Chemotherapy
- NCT02601339 · 70 participants
NIRS Monitoring in Premature Infants
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI